Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.55 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.55 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.44 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.44 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | MMP1 | P03956 | 2/20 | 0.43 |
| ▸ | MMP2 | P08253 | 2/20 | 0.43 |
| ▸ | MMP9 | P14780 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11533429 | 0.85 | CYP2C9 (0.65) | CYP2D6CYP2C19CYP1A2CYP2C9TSHR | |
| SCHEMBL8602062 | 0.83 | CYP2C9 (0.59) | CYP2D6CYP2C19CYP1A2CYP2C9TSHR | |
| SCHEMBL13920457 | 0.82 | EPHX2 (0.54) | EPHX2NR1H4CYP2C19CYP2C9ALDH1A1 | |
| SCHEMBL3113924 | 0.82 | KMT2A (0.59) | EPHX2NR1H4ALDH1A1SMN1; SMN2HDAC3 | |
| SCHEMBL14341628 | 0.82 | CYP2D6 (0.50) | CYP2D6CYP2C19CYP1A2CYP2C9TSHR | |
| SCHEMBL2701023 | 0.82 | CYP2C9 (0.61) | EPHX2NR1H4CYP2C19CYP2C9ALDH1A1 | |
| SCHEMBL1935713 | 0.81 | MMP1 (0.46) | ALDH1A1LMNASMN1; SMN2MAPTMMP1 | |
| SCHEMBL22060061 | 0.79 | EPHX2 (0.55) | EPHX2NR1H4ALDH1A1LMNAHDAC3 | |
| SCHEMBL28424688 | 0.79 | NR1H4 (0.71) | EPHX2NR1H4ALDH1A1HDAC3HDAC1 | |
| SCHEMBL28430381 | 0.79 | NR1H4 (0.71) | EPHX2NR1H4ALDH1A1HDAC3HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024107615-A1 | OREXIN RECEPTOR AGONISTS | MERCK SHARP & DOHME LLC (US) | 2024-05-23 | — | — | WO | disclosed |
| EP-3921320-B1 | IMIDAZO [2, 1-F] [1, 2, 4] TRIAZIN-4-AMINE DERIVATIVES AS TLR7 AGONIST | BEIGENE LTD (KY) | 2024-03-06 | — | — | EP | disclosed |
| US-11802135-B2 | Lysophosphatidic acid derivative | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2023-10-31 | — | — | US | disclosed |
| US-11673889-B2 | Substituted imidazo[4,5-c][1,8]naphthyridines as phosphodiesterase inhibitors | NANJING ZHENGXIANG PHARMACEUTICALS CO., LTD. (CN) | 2023-06-13 | — | — | US | disclosed |
| US-20230146210-A1 | NOVEL LYSOPHOSPHATIDIC ACID DERIVATIVE | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2023-05-11 | — | — | US | disclosed |
| US-20230014730-A1 | PHOSPHODIESTERASE INHIBITORS AND USE | NANJING ZHENGXIANG PHARMACEUTICALS CO., LTD. (CN) | 2023-01-19 | — | — | US | disclosed |
| US-20220220114-A1 | PHOSPHODIESTERASE INHIBITORS AND USE | NANJING ZHENGXIANG PHARMACEUTICALS CO., LTD. (CN) | 2022-07-14 | — | — | US | disclosed |
| US-20220119394-A1 | IMIDAZO[2,1-F][1,2,4]TRIAZIN-4-AMINE DERIVATIVES AS TLR7 AGONIST | BEONE MEDICINES I GMBH (CH) | 2022-04-21 | — | — | US | disclosed |
| WO-2021061803-A1 | PHOSPHODIESTERASE INHIBITORS AND USE | NANJING ZHENGXIANG PHARMACEUTICALS CO., LTD. (CN) | 2021-04-01 | — | — | WO | disclosed |
| US-10730862-B2 | Compounds and methods for the enhanced degradation of targeted proteins and other polypeptides by an E3 ubiquitin ligase | YALE UNIVERSITY (US) | 2020-08-04 | — | — | US | disclosed |
| US-20090137545-A1 | Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-05-28 | — | — | US | disclosed |
| EP-2042503-A1 | COMPOUND HAVING ACIDIC GROUP WHICH MAY BE PROTECTED, AND USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2009-04-01 | — | — | EP | disclosed |
| WO-2009001021-A1 | IMIDAZOPYRIDINE DERIVATIVES USEFUL AS ENZYME INHIBITORS FOR THE TREATMENT OF CELL PROLIFERATIVE AND AUTOIMMUNE DISEASES | CHROMA THERAPEUTICS LTD. (GB) | 2008-12-31 | — | — | WO | disclosed |
| WO-2008040934-A1 | HDAC INHIBITORS | CHROMA THERAPEUTICS LTD. (GB) | 2008-04-10 | — | — | WO | disclosed |
| US-20060276433-A1 | Hydrazone derivative | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2006-12-07 | — | — | US | disclosed |
| WO-2006083673-A2 | PYRIDINE DERIVATIVES USEFUL AS INHIBITORS OF C-JUN N-TERMINAL KINASES | ABBOTT LABORATORIES (US) | 2006-08-10 | — | — | WO | disclosed |
| EP-1612204-A1 | HYDRAZONE DERIVATIVE | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2006-01-04 | — | — | EP | disclosed |
| US-20030232860-A1 | Medicine comprising dicyanopyridine derivative | ASTELLAS PHARMA INC. (JP) | 2003-12-18 | — | — | US | disclosed |
| EP-1302463-A1 | MEDICINE COMPRISING DICYANOPYRIDINE DERIVATIVE | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 2003-04-16 | — | — | EP | disclosed |
| WO-2002089782-A2 | DIOXANES AND USES THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2002-11-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137545-A1 | Compounds | ADORA2B, ABCB11, CYP11B1 | EPHX2 428/4885NR1H4 69/4885CYP2D6 12/4885 |
| US-11802135-B2 | Lysophosphatidic acid derivative | LPAR4, LPAR2, LPAR1 | EPHX2 503/4885NR1H4 261/4885CYP2D6 4572/4885 |
| US-10730862-B2 | Compounds and methods for the enhanced degradation of targeted proteins and other polypeptides by an E3 ubiquitin ligase | VHL, MDM2, NEDD4 | EPHX2 2234/4885NR1H4 1895/4885CYP2D6 4340/4885 |
| US-20220119394-A1 | IMIDAZO[2,1-F][1,2,4]TRIAZIN-4-AMINE DERIVATIVES AS TLR7 AGONIST | TLR7, TLR1, TLR3 | EPHX2 4059/4885NR1H4 140/4885CYP2D6 3114/4885 |
| US-20030232860-A1 | Medicine comprising dicyanopyridine derivative | KCNN3, KCNN2, KCNN1 | EPHX2 4561/4885NR1H4 3703/4885CYP2D6 1890/4885 |
| US-11673889-B2 | Substituted imidazo[4,5-c][1,8]naphthyridines as phosphodiesterase inhibitors | ENPP1, ENPP3, PDE4A | EPHX2 1081/4885NR1H4 2579/4885CYP2D6 1106/4885 |
| US-20060276433-A1 | Hydrazone derivative | APP, PRNP, HTT | EPHX2 3561/4885NR1H4 1973/4885CYP2D6 3019/4885 |
| US-20230146210-A1 | NOVEL LYSOPHOSPHATIDIC ACID DERIVATIVE | LPAR4, LPAR2, LPAR1 | EPHX2 503/4885NR1H4 281/4885CYP2D6 4687/4885 |
| US-20220220114-A1 | PHOSPHODIESTERASE INHIBITORS AND USE | ENPP1, ENPP3, PDE4A | EPHX2 705/4885NR1H4 4183/4885CYP2D6 2707/4885 |
| US-20230014730-A1 | PHOSPHODIESTERASE INHIBITORS AND USE | ENPP1, ENPP3, PDE4A | EPHX2 705/4885NR1H4 4183/4885CYP2D6 2707/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.